Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 125 citing articles:

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Sebastian P. Haen, Markus Löffler, Hans‐Georg Rammensee, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 595-610
Open Access | Times Cited: 167
Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements
Nakul M. Shah, H. Josh Jang, Yonghao Liang, et al.
Nature Genetics (2023) Vol. 55, Iss. 4, pp. 631-639
Closed Access | Times Cited: 87
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Abhijeet Pataskar, Julien Champagne, Remco Nagel, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 721-727
Open Access | Times Cited: 84
Challenges in developing personalized neoantigen cancer vaccines
Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe
Nature reviews. Immunology (2023) Vol. 24, Iss. 3, pp. 213-227
Closed Access | Times Cited: 77
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes
Julien Racle, Philippe Guillaume, Julien Schmidt, et al.
Immunity (2023) Vol. 56, Iss. 6, pp. 1359-1375.e13
Open Access | Times Cited: 60
The impact of immunopeptidomics: From basic research to clinical implementation
Ilja E. Shapiro, Michal Bassani‐Sternberg
Seminars in Immunology (2023) Vol. 66, pp. 101727-101727
Open Access | Times Cited: 47
Computational Prediction and Validation of Tumor-Associated Neoantigens
Vladimir Roudko, Benjamin Greenbaum, Nina Bhardwaj
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 98
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Peter M.K. Westcott, Nathan Sacks, Jason M. Schenkel, et al.
Nature Cancer (2021) Vol. 2, Iss. 10, pp. 1071-1085
Open Access | Times Cited: 98
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy
Jingjing Qu, Farhin Shaheed Kalyani, Li Liu, et al.
Cancer Communications (2021) Vol. 41, Iss. 12, pp. 1331-1353
Open Access | Times Cited: 97
Peptidomics: A Review of Clinical Applications and Methodologies
Rachel E. Foreman, Amy L. George, Frank Reimann, et al.
Journal of Proteome Research (2021) Vol. 20, Iss. 8, pp. 3782-3797
Closed Access | Times Cited: 72
Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
HuiSong Pak, Justine Michaux, Florian Huber, et al.
Molecular & Cellular Proteomics (2021) Vol. 20, pp. 100080-100080
Open Access | Times Cited: 70
Functional Differences between Proteasome Subtypes
Joanna Abi Habib, Julie Lesenfants, Nathalie Vigneron, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 421-421
Open Access | Times Cited: 55
Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
Wenwen Wang, Tinggan Yuan, Lili Ma, et al.
Advanced Science (2022) Vol. 9, Iss. 22
Open Access | Times Cited: 37
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Jens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan Yuan, Fan Gao, Ying Chang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer
Jialong Zhu, Linlin Ji, Yitian Chen, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 36
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
Jan Dörrie, Niels Schaft, Gerold Schuler, et al.
Pharmaceutics (2020) Vol. 12, Iss. 2, pp. 92-92
Open Access | Times Cited: 61
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Xiaonan Zhang, Tobias Sjöblom
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 57-57
Open Access | Times Cited: 42
A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics
Xiaokang Li, Hui Song Pak, Florian Huber, et al.
Cell Reports Methods (2023) Vol. 3, Iss. 6, pp. 100479-100479
Open Access | Times Cited: 17
Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery
Charlotte Stutzmann, Jiaxi Peng, Zhaoguan Wu, et al.
Cell Reports Methods (2023) Vol. 3, Iss. 6, pp. 100511-100511
Open Access | Times Cited: 17
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 12, pp. 2250-2265
Open Access | Times Cited: 16
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Siqi Zhang, Jieting Shen, Xingkai Wang, et al.
View (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 16
Monocyte/Macrophage‐Mediated Transport of Dual‐Drug ZIF Nanoplatforms Synergized with Programmed Cell Death Protein‐1 Inhibitor Against Microsatellite‐Stable Colorectal Cancer
Xietao Ye, Yuping Liu, Liangyin Wei, et al.
Advanced Science (2024) Vol. 11, Iss. 38
Open Access | Times Cited: 6
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Antonin Lévy, Daphné Morel, Matthieu Texier, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top